… proteins downstream of BCR-ABL in CML cells. K562 and K562R cells were treated with 0,
5… In conclusion, SH-4-54 could overcome imatinib resistant and may be a promising treatment …

… in imatinib‑resistant cells reinstates imatinib susceptibility. … target of the second generation
BCR::ABL1 inhibitor dasatinib (… inhibitor of the Abl tyrosine kinase on the growth of Bcr‑Abl …

… of BCR::ABL tyrosine kinase inhibitor (TKI) has been a gamechanger in the treatment of …
In a phase 1 study, imatinib-resistant or -intolerant patients treated with single-agent dasatinib …

… In this trial, 150 imatinib-resistant patients with CP-CML were randomized to high-dose
imatinib or dasatinib. Dasatinib demonstrated significantly better rates of hematologic and …

… The antileukemia effects of CPT and Bcr-Abl tyrosine kinase inhibitors in imatinib resistant …
CPT and imatinib as well as second-generation Bcr-Abl tyrosine kinase inhibitors. Our results …

… first second generation TKI was approved by both the US FDA and the EMA for the treatment
of imatinib-resistant … imatinib in inhibiting Bcr-Abl tyrosine kinase activity and proliferation of …

… -positive chronic phase-chronic myeloid leukemia, initially treated … be able to overcome
several imatinib-resistant KD mutations. Ergo… in BCR-ABL KD are the leading cause of secondary …

… included patients who were imatinib resistant or intolerant. … with chronic myeloid leukemia
progression and with chronic … -2 and BCR-ABL tyrosine kinase eradicates chronic myeloid …

… -intolerant patients than in imatinib-resistant patients (CCyR: 100… In addition, in imatinib-resistant
patients, the cumulative … TKI treatment, but do not proliferate due to the lack of BCR-ABL …

… In the treatment of chronic myeloid leukemia (CML), resistance to … CML who show resistance
to BCR-ABL inhibitors. Thus, we established multiple imatinib-resistant K562 cell lines and …